SCHEDULE: FMR LLC, Abigail Johnson Report 4.3% Stake in Royalty Pharma

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, disclosing beneficial ownership of 19,288,880.43 shares, representing 4.3% of Royalty Pharma PLC's Class A Common Stock as of September 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Royalty Pharma PLC's Class A Common Stock.
• As of September 30, 2026, the total number of shares beneficially owned is 19,288,880.43.
• This ownership stake represents 4.3% of the total outstanding Class A Common Stock.
• FMR LLC holds sole voting power over 14,091,863.23 shares and sole dispositive power over 19,288,880.43 shares.
• Abigail P. Johnson also has sole dispositive power over 19,288,880.43 shares.
• The filing confirms that no single other person's interest in the Class A Common Stock exceeds five percent.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not dominant ownership stake by FMR LLC and Abigail P. Johnson in Royalty Pharma PLC.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant, albeit not controlling, ownership stake in Royalty Pharma PLC.
• The filing clarifies the ownership structure and beneficial holdings, providing transparency to the market.
• The reported stake of 4.3% indicates continued investment and confidence in Royalty Pharma PLC by major financial entities.

Negatives

• The filing does not contain any negative financial performance indicators or operational challenges.
• No specific reasons for the ownership level are provided, leaving the strategic intent open to interpretation.

Risks

• The filing does not explicitly mention any risks associated with the ownership stake itself.
• Potential future changes in ownership by FMR LLC or Abigail P. Johnson could impact Royalty Pharma PLC's stock price.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future ownership or investment strategies.

Management Comments

• FMR LLC and Abigail P. Johnson may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC through their ownership of voting common shares and the shareholders' voting agreement.
• This filing reflects securities beneficially owned by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters').

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant institutional investors. The 4.3% stake by FMR LLC and Abigail P. Johnson in Royalty Pharma PLC places them among the larger institutional holders, reflecting active portfolio management within the pharmaceutical and biotechnology investment sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes can influence investor confidence and market perception.
• Management of Royalty Pharma PLC: Awareness of substantial holdings by major financial entities like FMR LLC is important for strategic planning and investor relations.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership of Royalty Pharma PLC's Class A Common Stock.
• Future filings will be made if ownership levels change significantly.

Key Dates

Keywords

Royalty Pharma PLC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Management, Shareholder